(Reuters) – 1/VACCINE RACE

U.S. President Donald Trump has put his faith in anti-malarial drug hydroxychloroquine to ward off COVID-19, but governments and investors are focusing on a vaccine. Without one, it’s unlikely economic activity can resume fully.

So the race is on, and the rewards are rich: AstraZeneca (L:AZN) has vaulted into the position of the most valuable British company after receiving a U.S.